Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Branaplam

Generic Name: Branaplam

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₇N_₅O_₂

CAS Number: 1562338-42-4

Unique Ingredient Identifier: P12R69543A

Overview

Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

Background

Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

Indication

用于治疗亨廷顿氏病（HD，是一种罕见的遗传性神经退行性疾病）。

Associated Conditions

No associated conditions information available.

Clinical Trials

Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Phase 1

Terminated

Posted: 2022/04/15

Sponsor:Novartis Pharmaceuti...

ID:NCT05330286

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

Phase 2

Terminated

Posted: 2021/11/08

Sponsor:Novartis Pharmaceuti...

ID:NCT05111249

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

Phase 1

Completed

Posted: 2014/10/20

Sponsor:Novartis Pharmaceuti...

ID:NCT02268552

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy

Drug Development Updates

Branaplam

Overview

Background

Indication

Associated Conditions

Clinical Trials

FDA Approved Products

Singapore Approved Products

Related News

Novartis and PTC Therapeutics Collaborate on Huntington's Disease Treatment with PTC518

Drug Development Updates